The invention relates to the use of a gaseous drug based on gaseous xenon for inhalation for treating or preventing in mammals dyskinesia induced by a dopaminergic agonist. The invention is particularly useful for treating levodopa induced dyskinesia in patients being treated for Parkinsons disease.